证券代码：301103 证券简称：何氏眼科 公告编号：2025-032 辽宁何氏眼科医院集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次股东大会无增加、变更、否决提案的情况。 2.本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）2025 年第一次临 时股东大会于 2025 年 9 月 15 日召开，公司董事会已于 2025 年 8 月 28 日在巨潮 资讯网上刊登了《关于召开 2025 年第一次临时股东大会的通知》。 本次股东大会由公司董事会召集，现场会议由公司董事周晋峰先生主持，会 议召开符合《公司法》《上市公司股东大会规则》《深圳证券交易所创业板股票上 市规则》及《公司章程》等规定。 1.会议召开方式：本次股东大会采用现场和网络投票相结合的方式召开。 2.会议召开日期和时间： 现场会议时间为：2025 年 9 月 15 日（星期一）14:00 网络投票时间为：2025 年 9 月 15 日（星期一） 其中 ...

北京市中伦律师事务所 关于辽宁何氏眼科医院集团股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年九月 北京市中伦律师事务所 关于辽宁何氏眼科医院集团股份有限公司 2025 年第一次临时股东大会的 法律意见书 议审议的议案内容以及这些议案所表述的事实或数据的真实性及准确性发表意 见。本所律师无法对网络投票股东资格进行核查，在参与网络投票的股东资格均 符合法律、行政法规、规范性文件规定及《公司章程》规定的前提下，相关出席 会议股东符合资格。 法律意见书 致：辽宁何氏眼科医院集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受辽宁何氏眼科医院集团股 份有限公司（以下简称"公司"）委托，指派本所律师对公司 2025 年第一次临时 股东大会（以下简称"本次股东大会"）的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规则》 （以下简称"《股东会规则》"）等现行有效的法律、法规和规范性文件以及《辽 宁何氏眼科医院集团股份有限公司章程》（以下简称"《公司章程》"）的规定 而出具 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2025-033 辽宁何氏眼科医院集团股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事辞职情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）董事会于近日收到 公司非独立董事李萍萍女士递交的书面辞职报告。因公司董事会成员架构调整及 《公司章程》修订等原因，李萍萍女士申请辞去公司第三届董事会非独立董事职 务，辞任后不再担任公司其他职务。根据《公司法》及《公司章程》等有关规定， 李萍萍女士辞任董事不会导致公司董事会成员低于法定最低人数，不会影响公司 董事会的正常运作，其辞任报告自送达公司董事会时生效。 李萍萍女士担任公司非独立董事的原定任期届满之日为 2026 年 8 月 9 日。 截至本公告披露日，李萍萍女士未直接持有公司股份，亦不存在应当履行而未履 行的承诺事项。公司董事会对李萍萍女士任职期间为公司发展所做出的贡献表示 衷心的感谢！ 二、选举职工代表董事情况 根据《公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管 ...

Core Viewpoint - The article discusses the evolving landscape of the medical device industry in China, highlighting the importance of business development (BD) strategies that go beyond mere numbers to encompass strategic partnerships, market expansion, and technological integration [1][24]. Group 1: Key Trends in Medical Device BD - The primary keywords for the period from July to September include cross-border introduction and global distribution, strategic cooperation, and capital and cross-industry integration [2]. - Companies are accelerating market expansion and ecosystem building through transactions across various fields, including cardiovascular, neuro-intervention, ophthalmology, IVD, and critical care [3]. Group 2: Representative Events - A total of 20 significant events were summarized, showcasing a "multi-line advancement" scenario in the industry [4]. - Notable collaborations include: - Nanjing Jianxin Medical and Heqi Family Office focusing on medical device R&D and wealth management [6]. - Olympus and Xingchenhai Medical signing a global distribution agreement for disposable urology products [6]. - He’s Eye Group and Zeiss China Medical forming a strategic partnership to enhance ophthalmic surgical technology [6]. Group 3: Cross-Border and Global Distribution - Cross-border transactions remain a hot topic, with domestic companies leveraging global markets for growth while foreign giants introduce Chinese innovations [9]. - The partnership between Ruichao Dinkai Group and Beijing Amite focuses on vascular intervention products, marking a new phase in safety standards [7]. Group 4: Strategic Cooperation and Channel Expansion - Strategic cooperation is increasingly focused on building ecosystems rather than single product breakthroughs, with companies forming partnerships in fields like ophthalmology, IVD, and diagnostics [19]. - The collaboration between Wanfu Biological and Beiden Medical aims to match products with non-public medical channels effectively [15]. Group 5: Capital Support and Cross-Industry Integration - Capital is becoming an invisible driver of medical device BD, with partnerships exploring new models for medical device distribution [20]. - The collaboration between Beijing Huamai Supply Chain Management and Hongyi Consulting aims to create a one-stop service for medical device distribution [20]. Group 6: Smart Hospitals and Full-Chain Coordination - The focus on smart hospitals and full-chain coordination is becoming a priority for large enterprises, integrating supply chains, academic promotion, and clinical needs [23]. - Collaborations like that of Ruibo Zehou Technology and China National Pharmaceutical Group aim to develop automated systems for smart hospitals [21]. Conclusion - The medical device industry in China is transitioning from a "single product-driven" phase to a more diversified approach supported by capital, channels, and ecosystems, indicating a long-term growth trajectory [24].

Core Insights - The company indicates that the third quarter, which includes the summer vacation, is a peak demand season for youth myopia prevention, refractive surgery, and medical optical fitting services [1] Industry Summary - The demand for consumer medical projects related to myopia prevention and correction is generally high during the third quarter, reflecting a common trend in the industry [1] - It is noted that the third quarter represents a peak season for certain projects, but not for the overall business of the company [1]

Core Viewpoint - He Eye Hospital emphasizes the importance of market value management, focusing on core business operations and maintaining a balance between intrinsic and market value to protect long-term shareholder interests [2] Group 1: Company Strategy - The company is committed to systematic market value management through improved corporate governance and operational quality [2] - He Eye Hospital plans to enhance cash dividend planning and investor relations management [2] Group 2: Investor Relations - The company prioritizes investor interests and aims to maintain a dynamic balance between intrinsic and market value [2] - Continuous improvement in information disclosure is part of the company's strategy to strengthen investor relations [2]

Core Viewpoint - He Eye Hospital focuses on comprehensive eye health management, including clinical diagnosis, vision services, and related health services, with no significant impact on current operations or performance from its drug development initiatives [2] Group 1: Business Focus - The company specializes in full lifecycle eye health management, which encompasses clinical diagnosis and vision services [2] - The main business areas include clinical diagnosis, vision services, and related health services [2] Group 2: Drug Development - The company's drug development efforts are primarily concentrated on in-hospital formulation research, exploration of traditional Chinese medicine new drugs, and clinical application collaborations with innovative drugs/technologies [2] - There is currently no independent research and development in innovative drugs [2] Group 3: Investor Advisory - The company has advised investors to be cautious regarding investment risks, particularly in relation to its drug development activities [2]

Group 1 - The core viewpoint of the news is the strategic partnership between He Eye Hospital Group and Johnson & Johnson Vision Care, aimed at enhancing eye health services in China through innovative technologies and personalized solutions [1][2] - The collaboration includes the establishment of two strategic cooperation groups: the "Presbyopia Diagnosis and Treatment Center Strategic Cooperation Group" and the "Global Innovative Technology for Refractive Cataract Strategic Cooperation Group," focusing on clinical value verification and application of cutting-edge technologies [1] - He Eye Hospital aims to leverage its comprehensive clinical resources and research platforms to achieve its goal of becoming a "Smart Bright City," enhancing patient care through technology and innovation [1] Group 2 - The partnership is expected to drive the integration of precision medicine and smart healthcare, providing high-quality eye health management services throughout the lifecycle of patients [2] - He Eye Hospital plans to collaborate with global partners to gather resources and promote the development of eye health, contributing to the overall health of the Chinese population and the global eye health sector [2]

Core Insights - The strategic partnership between He Eye Hospital Group and Zeiss China Medical aims to enhance the quality and precision of ophthalmic surgeries, particularly in cataract and refractive procedures [1][2] Group 1: Strategic Collaboration - He Eye Hospital and Zeiss China Medical have established six specialized technical cooperation units focusing on complex ophthalmic issues such as cataracts, high myopia correction, presbyopia correction, and astigmatism correction [1] - The collaboration signifies a new phase of deep technological integration, leveraging Zeiss's advanced optical technology and He Eye Hospital's extensive clinical resources [1][2] Group 2: Goals and Vision - The partnership aims to create a comprehensive innovation system from technology research and development to clinical application, promoting standardized and precise refractive cataract and presbyopia surgeries [1] - Both companies emphasize a patient-centered approach and the use of digital and intelligent methods to enhance access to quality ophthalmic resources across regions, contributing to the "Healthy China" strategy [2]

Group 1 - The core viewpoint of the article is the launch of the upgraded "Vision Light" training program by Liaoning He Eye Hospital Group, which aims to respond to the national eye health strategy by training a significant number of eye care professionals [1] - The training program is supported by the National Health Commission's blindness prevention training base and Liaoning He Medical College, focusing on systematic, large-scale, and precise training [1] - The program aims to cultivate 100 leaders in ophthalmology and optometry, 1,000 technical backbone talents, and 10,000 grassroots professionals over the coming years, establishing a talent pipeline for the entire eye health industry [1] Group 2 - The initiative is expected to enhance the quality and accessibility of eye care services in China by gathering expert knowledge and industry resources [1]